TMCI Deadline: Rosen Law Firm Urges Treace Medical Concepts, Inc. (NASDAQ: TMCI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds…
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In…
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the…
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a…
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than…
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma
Phase III NAPOLI 3 trial is the largest and has the longest…
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33…
LINKIN PARK ROCK THE UEFA CHAMPIONS LEAGUE FINAL KICK OFF SHOW PRESENTED BY PEPSI
MILLIONS OF FANS FROM ACROSS THE WORLD TUNED IN TO WATCH THE…
